3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
41
Leukemia
34
Lymphoma
22
Myelodysplastic Syndromes
16
Hodgkin Disease
16
Precursor Cell Lymphoblastic Leukemia-Lymphoma
12
Multiple Myeloma
10
Lymphoma, Non-Hodgkin
10
Lymphoma, Mantle-Cell
9
Leukemia, Myeloid, Acute
9
Recurrence
8
Myeloproliferative Disorders
8
Lymphoma, Large B-Cell, Diffuse
8
Lymphoma, Follicular
8
Lymphoma, B-Cell, Marginal Zone
8
Leukemia, Myeloid, Chronic-Phase
7
Anemia, Aplastic
7
Waldenstrom Macroglobulinemia
6
Lymphoma, T-Cell, Peripheral
6
Congenital Abnormalities
6
Burkitt Lymphoma
6
Sezary Syndrome
5
Primary Myelofibrosis
5
Neoplasms, Plasma Cell
5
Mycosis Fungoides
5
Lymphoma, Large-Cell, Immunoblastic
5
Graft vs Host Disease
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Myelodysplastic-Myeloproliferative Diseases
4
Lymphoma, T-Cell, Cutaneous
4
Interventions
Cyclophosphamide
9
Rituximab
6
Tacrolimus
5
Busulfan
5
fludarabine phosphate
4
blinatumomab
4
Vincristine
4
Prednisone
4
Peripheral Blood Stem Cell Transplantation
4
Mycophenolic Acid
4
Etoposide
4
Doxorubicin
4
fludarabine
3
Whole-Body Irradiation
3
Valganciclovir
3
Everolimus
3
venetoclax
2
dacetuzumab
2
cobomarsen
2
Thiotepa
2
Sirolimus
2
Patient Reported Outcome Measures
2
Methotrexate
2
Mesna
2
Melphalan
2
Filgrastim
2
Epoetin Alfa
2
Antilymphocyte Serum
2
sargramostim
1
pomalidomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Lymphoproliferative Disorders
×
Alemtuzumab
×
Clear all
NCT00368355
2020-01-21
MOHEL
Baylor College of Medicine
Phase 2
Completed
46 enrolled
12 charts